A phase Ib study of everolimus combined with metformin for patients with advanced cancer

Background The efficacy to monotherapy with the mTOR inhibitor everolimus in advanced cancer is often limited due to therapy resistance. Combining everolimus with metformin may decrease the chance of therapy resistance. Methods Patients received everolimus and metformin in a 3 + 3 dose-escalation sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Molenaar, Remco J., van de Venne, Tim, Weterman, Mariëtte J., Mathot, Ron A., Klümpen, Heinz-Josef, Richel, Dick J., Wilmink, Johanna W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805805/
https://www.ncbi.nlm.nih.gov/pubmed/28616837
http://dx.doi.org/10.1007/s10637-017-0478-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805805/
https://www.ncbi.nlm.nih.gov/pubmed/28616837
http://dx.doi.org/10.1007/s10637-017-0478-4

Ejemplares similares